- Alto Neuroscience employs a **biomarker-driven platform** utilizing tools like EEG and cognitive tests to select patients and de-risk drug development, an approach that aligns with **FDA enrichment guidelines**.  **[1999480_2146318_0]** **[1999480_2146318_1]** 
- The company provided updates on its late-stage pipeline, including **ALTO-101** (cognitive impairment in schizophrenia) with topline data anticipated in the **second half of next year**, and **ALTO-207** (treatment-resistant depression), acquired from Chase Therapeutics, which will begin its Phase IIB trial in the **first half of next year**.  **[1999480_2146318_2]** **[1999480_2146318_5]**  ALTO-207 previously demonstrated strong efficacy with Cohen's D values of **0.9 to 1.1** in prior studies.  **[1999480_2146318_3]** **[1999480_2146318_4]** 
- For **ALTO-300** (adjunctive depression treatment), the Phase IIB study was upsizing after a positive interim analysis, with enrollment completion projected for **mid-next year**.  **[1999480_2146318_2]** **[1999480_2146318_6]** **[1999480_2146318_7]** 
- To improve data quality and mitigate risks, Alto Neuroscience is implementing **higher rigor in its clinical trials**, including requiring medical/pharmacy records and blood/urine samples to confirm drug adherence.  **[1999480_2146318_7]**

Alto Neuroscience (ANRO)